After my post 2 months ago about the pressure I have received to stop doing this stem cell blog, I have been flooded with positive feedback (including by some of the top bigwigs in the stem cell field who chose to remain anonymous) and I have been inundated with questions. They had many different comments, […]
Who wants to shut down this stem cell blog and why? Read More »
What is a standing workstation? You know how when people give you bad news they ask “Are you sitting down?” Since I’m going to give you some good news in this post, I ask you now as you are reading this, are you standing up? We are constantly bombarded with news stories about what is
Two companies, Advanced Cell Technology (ACT) and Geron, both HQ’d here in California, have FDA-approved early stage clinical trials in the works. Geron’s trial has already started and reportedly now has enrolled at least two patients. The trial is of course for the safety of Geron’s GRNOPC1 oligodendrocyte product made from human ES cells for
Advanced Cell Technology and Geron: allies or competitors? Read More »
What really happens to cells after they a stem cell transplant into a patient? Once these cells, which have spent weeks in a lab environment, are injected into a person, what happens next? This is arguably the most important question in the regenerative medicine field, but there are few answers. We are literally mostly in
Stem cells gone wild? What really happens after a transplant Read More »
This past week was a wacky and wild one for the stem cell field. All kinds of crazy things happened all in one week. What does it all mean? Stem cells the new steroids for sports? Reports surface this week that NY Yankees pitcher Bartolo Colon, had received a non-FDA approved stem cell treatment for
A crazy week for stem cells: what the heck does it all mean? Read More »
Yesterday I ran a cancer stem cells meeting here at UC Davis School of Medicine. We had some great speakers and over 150 participants including our outstanding keynote speaker, Dr. Jeremy Rich, Director of Stem Cell Research at the Cleveland Clinic. One of the ideas percolating through the meeting was that during cancer development, there
Cancer stem cells and iPS cells Read More »
Six months ago, I published a Top 10 list of questions and predictions for the stem cell field. How did I do? A mixed bag. Below are the questions and predictions from October 2010 (in blue), along with an update as to how my predictions fared. 1) How will Geron’s Phase I Clinical Trial go?
Stem Cell Questions & Predictions: how did I do? Read More »
How are things looking for the stem cell field for Spring 2011? Issue One. Getting to the clinic. At this point, Geron and ACT have their FDA-approved clinical trials underway using derivatives of human embryonic stem cells. As expected no news has leaked out on how things are going and it may well be Fall
Update on the stem cell field: Spring 2011 Read More »
It’s been more than 4 years since Shinya Yamanaka published the remarkable finding that his lab could transform or “reprogram” regular cells called fibroblasts into a very unique state that was quite similar to that of embryonic stem cells (ESC). Yamanaka called these new cells “iPS cells” for induced pluripotent stem cells. iPS cells Since
The Inside Scoop on iPS cells early in 2011 Read More »
There is a kind of invisible cultural wall between patients such as cancer patients and biomedical scientists like me, but this wall does not have to exist and indeed it is a negative wall as patients, scientists, doctors, agencies, and advocates can achieve far more together than apart. But the wall is surprisingly strong. Last
My Cancer: how I became an advocate too Read More »